Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B01297b7bb477e3384528c4e85c2e8e27> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B01297b7bb477e3384528c4e85c2e8e27 NCIT_P378 "NCI" @default.
- B01297b7bb477e3384528c4e85c2e8e27 type Axiom @default.
- B01297b7bb477e3384528c4e85c2e8e27 annotatedProperty IAO_0000115 @default.
- B01297b7bb477e3384528c4e85c2e8e27 annotatedSource NCIT_C2919 @default.
- B01297b7bb477e3384528c4e85c2e8e27 annotatedTarget "An adenocarcinoma arising from the prostate gland. It is one of the most common malignant tumors afflicting men. The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland. Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival. Several grading systems have been proposed, of which the Gleason system is the most commonly used. Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease." @default.